LAYTON BIOSCIENCE INC has a total of 17 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Australia, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and agriculture are NAT UNIV CORP TOTTORI UNIV, JIKEI UNIVERSITY SCHOOL OF MED and IMPLYX LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Canada | 2 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Agriculture |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Animal care | |
#5 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Snable Gary L | 14 |
#2 | Mcgrogan Michael P | 9 |
#3 | Sanberg Paul R | 7 |
#4 | Kondziolka Douglas | 6 |
#5 | Snable Gary | 3 |
#6 | Aboody Karen S | 3 |
#7 | Hartley Dean | 2 |
#8 | Noll Elizabeth | 2 |
#9 | Daadi Mo | 1 |
#10 | Sanberg Paul | 1 |
Publication | Filing date | Title |
---|---|---|
AU2005202666A1 | Cell therapy for chronic stroke | |
AU2002251681A1 | Production and use of dopaminergic cells to treat dopaminergic deficiencies | |
WO0213837A1 | A novel animal model of alzheimer's disease using genetically altered stem cells | |
WO0064459A1 | Cell therapy for chronic stroke | |
EP1949904A2 | Cell therapy for chronic stroke | |
EP1109887A1 | Production and use of dopaminergic cells to treat dopaminergic deficiencies | |
US6162428A | hNT-neuron human neuronal cells to replace ganglion cells |